Hepatic encephalopathy

Cirrhosis: A Practical Guide to Management

Volumn , Issue , 2015, Pages 105-123

  Amodio, Piero ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Ammonia; Branched chain amino acids; EEG; Glycerol phenylbutyrate; L ornithine L aspartate; Lactulose; Ornitine phenylacetate; Probiotics; Psychometric tests; Rifaximine

Indexed keywords

EID: 84961681687     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118412640.ch11     Document Type: Chapter

References (152)

1. Moffat J. Prognostics and Prorrhetics of Hippocrates, translated from the original Greek. London, UK: Bensley, 1788.
2. Walshe JM. Observations on the symptomatology and pathogenesis of hepatic coma. Q J Med 1951;20:421-38.
3. Adams RD, Foley JM. The neurological disorder associated with liver disease. Res Publ Assm Res Nerv Ment Dis 1953;32:198-237.
4. Sherlock S, Summerskill WHJ, White LP, Phear EA. Portalsystemic encephalopathy: neurological complications of liver disease. Lancet 1954;267:454-7.
5. Fazekas JE, Ticktin HE, Shea JG. effects of L-arginine on hepatic encephalopathy. Am J Med Sci 1957;234:462-7.
6. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715-35.
7. Cadranel JF, Lebiez E, Di Martino V, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Am J Gastroenterol 2001;96:515-8.
8. Victor M, Adams RD, Cole M. The acquired (non Wilsonian) type of chronic hepatocerebral degeneration. Medicine 1965;44:345-96.
9. Baccarani U, Zola E, Adani GL, et al. Reversal of hepatic myelopathy after liver transplantation: fifteen plus one. Liver Transpl 2010;16:1336-7.
10. Weissenborn K, Tietge UJ, Bokemeyer M, et al. Liver transplantation improves hepatic myelopathy: evidence by three cases. Gastroenterology 2003;124:346-51.
11. Mendoza G, Marti-Fabregas J, Kulisevsky J, Escartin A. Hepatic myelopathy: a rare complication of portacaval shunt. Eur Neurol 1994;34:209-12.
12. Cordoba J, Cabrera J, Lataif L, Penev P, Zee P, Blei AT. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998;27:339-45.
13. Mostacci B, Ferlisi M, Baldi AA, et al. Sleep disturbance and daytime sleepiness in patients with cirrhosis: a case control study. Neurol Sci 2008;29:237-40.
14. Montagnese S, Middleton B, Skene DJ, Morgan MY. Nighttime sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis. Liver Int 2009;29:1372-82.
15. Roman E, Cordoba J, Torrens M, Guarner C, Soriano G. Falls and cognitive dysfunction impair health-related quality of life in patients with cirrhosis. Eur J Gastroenterol Hepatol 2013;25:77-84.
16. Soriano G, Roman E, Cordoba J, et al. Cognitive dysfunction in cirrhosis is associated with falls: a prospective study. Hepatology 2012;55:1922-30.
17. Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004;19:253-67.
18. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011;33:739-47.
19. Ortiz M, Cordoba J, Doval E, et al. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther 2007;26:859-67.
20. Hassanein TI, Hilsabeck RC, Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci 2008;53:529-38.
21. Salam M, Matherly S, Farooq IS, et al. Modified-orientation log to assess hepatic encephalopathy. Aliment Pharmacol Ther 2012;35:913-20.
22. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portalsystemic encephalopathy: a double blind controlled trial. Gastroenterology 1977;72:573-83.
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
24. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification. Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-21.
25. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468-75.
26. Coltorti M, Del Vecchio-Blanco C, Caporaso N, Gallo C, Castellano L. Liver cirrhosis in Italy: a multicentre study on presenting modalities and the impact on health care resources. National Project on Liver Cirrhosis Group. Ital J Gastroenterol 1991;23:42-8.
27. Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010;138:2332-40.
28. Riggio O, Ridola L, Pasquale C, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2011;9:181-3.
29. Gentilini P, Laffi G, La Villa G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 1997;92:66-72.
30. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7:122-8.
31. Jmaa A, Ksiaa M, Ben SA, et al. The natural history of hepatitis B virus cirrhosis after the first hepatic decompensation in Tunisia. Tunis Med 2012;90:172-6.
32. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-91, 891.
33. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362: 1071-81.
34. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-59.
35. Amodio P, Pellegrini A, Ubiali E, et al. The EEG assessment of low-grade hepatic encephalopathy: comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis. Clin Neurophysiol 2006;117:2243-51.
36. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology 2010;51:306
37. Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene- covered stent grafts. Am J Gastroenterol 2008;103:2738-46.
38. Spina G, Santambrogio R. The role of portosystemic shunting in the management of portal hypertension. Bailliere Clin Gastroenterol 1992;6:497-515.
39. Bai M, Qi X, Yang Z, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol 2011;26:943-51.
40. Stepanova M, Mishra A, Venkatesan C, Younossi ZM. Inhospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012;10:1034-41.
41. Del Piccolo F, Sacerdoti D, Amodio P, et al. Central nervous system alterations in liver cirrhosis: the role of portal-systemic shunt and portal hypoperfusion. Metab Brain Dis 2002;17:347-58.
42. Garcia-Martinez R, Simon-Talero M, Cordoba J. Prognostic assessment in patients with hepatic encephalopathy. Dis Markers 2011;31:171-9.
43. Watanabe A. Portal-systemic encephalopathy in non-cirrhotic patients: classification of clinical types, diagnosis and treatment. J Gastroenterol Hepatol 2000;15:969-79.
44. Keiding S, Munk OL, Roelsgaard K, Bender D, Bass L. Positron emission tomography of hepatic first-pass metabolism of ammonia in pig. Eur J Nucl Med 2001;28:1770-5.
45. Aldrete JS. Quantification of the capacity of the liver to remove ammonia from the circulation of dogs with portacaval transposition. Surg Gynecol Obstet 1975;141: 399-404.
46. Riggio O, Mannaioni G, Ridola L, et al. Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol 2010;105:1374-81.
47. Nomura F, Ohnishi K, Terabayashi H, et al. Effect of intrahepatic portal-systemic shunting on hepatic ammonia extraction in patients with cirrhosis. Hepatology 1994;20: 1478-81.
48. Conn HO. Hepatic encephalopathy. In: Schiff L, Schiff ER (eds) Diseases of the Liver, 7th edn. Philadelphia: Lippicott, 1993. pp. 1036-60.
49. Arora S, Martin CL, Herbert M. Myth: interpretation of a single ammonia level in patients with chronic liver disease can confirm or rule out hepatic encephalopathy. CJEM 2006;8:433-5.
50. Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014;59:1073-83.
51. Fahn S. Classification of movement disorders. Mov Disord 2011;26:947-57.
52. Comim CM, Constantino LC, Barichello T, Streck EL, Quevedo J, Dal-Pizzol F. Cognitive impairment in the septic brain. Curr Neurovasc Res 2009;6:194-203.
53. Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005;62:2295-304.
54. Amodio P, Del Piccolo F, Petteno E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 2001;35:37-45.
55. Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535-42.
56. Butterworth RF. Thiamine deficiency-related brain dysfunction in chronic liver failure. Metab Brain Dis 2009;24:189-96.
57. Schomerus H, Hamster W. Neuropsychological aspects of portal-systemic encephalopathy. Metab Brain Dis 1998;13: 361-77.
58. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768-73.
59. Amodio P, Wenin H, Del Piccolo F, et al. Variability of trail making test, symbol digit test and line trait test in normal people: a normative study taking into account age-dependent decline and sociobiological variables. Aging Clin Exp Res 2002;14:117-31.
60. Dhiman RK, Saraswat VA, Verma M, Naik Sr. Figure connection test: a universal test for assessment of mental state. J Gastroenterol Hepatol 1995;10:14-23.
61. Dhiman RK, Kurmi R, Thumburu KK, et al. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci 2010;55:2381-90.
62. Randolph C, Hilsabeck R, Kato A, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009;29:629-35.
63. Riggio O, Ridola L, Pasquale C, et al. A simplified psychometric evaluation for the diagnosis of minimal hepatic encephalopathy. Clin Gastroenterol Hepatol 2011;9: 613-6.
64. Amodio P, Ridola L, Schiff S, et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology 2010;139:510-8.
65. Bajaj JS, Hafeezullah M, Franco J, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008;135:1591-600.
66. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quantification of lowgrade hepatic encephalopathy. Hepatology 2002;35:357-66.
67. Guerit JM, Amantini A, Fischer C, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009;29:789-96.
68. Parsons-Smith BG, Summerskill WHJ, Dawson AM, Sherlock S. The electroencephalograph in liver disease. Lancet 1957;273:867-71.
69. Amodio P, Marchetti P, Del Piccolo F, et al. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol 1999;110:1334-44.
70. Kato A, Suzuki K, Kaneta H, Obara H, Fujishima Y, Sato S. Regional differences in cerebral glucose metabolism in cirrhotic patients with subclinical hepatic encephalopathy using positron emission tomography. Hepatol Res 2000;17: 237-45.
71. Senzolo M, Pizzolato G, Ferronato C, Chierichetti F, Boccagni P, Dam M, Burra P. Long-term evaluation of cognitive function and cerebral metabolism in liver transplanted patients. Transplant Proc 2009;41:1295-6.
72. Giewekemeyer K, Berding G, Ahl B, Ennen JC, Weissenborn K. Bradykinesia in cirrhotic patients with early hepatic encephalopathy is related to a decreased glucose uptake of frontomesial cortical areas relevant for movement initiation. J Hepatol 2007;46:1034-9.
73. Lockwood AH, Weissenborn K, Bokemeyer M, Tietge U, Burchert W. Correlations between cerebral glucose metabolism and neuropsychological test performance in nonalcoholic cirrhotics. Metab Brain Dis 2002;17:29-40.
74. Weissenborn K, Bokemeyer M, Ahl B, et al. Functional imaging of the brain in patients with liver cirrhosis. Metab Brain Dis 2004;19:269-80.
75. Kostler H. Proton magnetic resonance spectroscopy in portal- systemic encephalopathy. Metab Brain Dis 1998;13: 291-301.
76. Amodio P, Pellegrini A, Amista P, et al. Neuropsychologicalneurophysiological alterations and brain atrophy in cirrhotic patients. Metab Brain Dis 2003;18:63-78.
77. Guevara M, Baccaro ME, Gomez-Anson B, et al. Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. J Hepatol 2011;55:564-73.
78. Zhang LJ, Yang G, Yin J, Liu Y, Qi J. Neural mechanism of cognitive control impairment in patients with hepatic cirrhosis: a functional magnetic resonance imaging study. Acta Radiol 2007;48:577-87.
79. Zhang LJ, Qi R, Zhong J, et al. Disrupted functional connectivity of the anterior cingulate cortex in cirrhotic patients without overt hepatic encephalopathy: a resting state fMRI study. PLoS One 2013;8:e53206.
80. Berding G, Banati RB, Buchert R, et al. Radiotracer imaging studies in hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009;29:621-8.
81. Butterworth RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, Blei AT. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009;29:783-8.
82. Van Caulert C, Deviller C, Halff M. Troubles provoques par l'ingestion de sels ammoniacaux chez l'homme atteint de cirrhose de Laennec. Comptes Rendus Soc Biol 1932;111:739-40.
83. Balo J, Korpassy B. The encephalitis of the dog with Eck fistula fed on meat. Arch Pathol 1932;13:80-7.
84. Stormont JM, Mackie JE, Davidson CS. Observations on antiobiotics in the treatment of hepatic coma and on factors contributing to prognosis. N Engl J Med 1958;259:1145-50.
85. Bircher J, Muller J, Guggenheim P, Haemmerli UP. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet 1966;1:890-2.
86. Baraldi M, Avallone R, Corsi L, Venturini I, Baraldi C, Zeneroli ML. Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy. Metab Brain Dis 2009;24:81-93.
87. Felipo V, Urios A, Montesinos E, et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis 2012;27:51-8.
88. Mannaioni G, Carpenedo R, Corradetti R, et al. Tryptophan metabolism and hepatic encephalopathy. Studies on the sedative properties of oxindole. Adv Exp Med Biol 1999;467:155-67.
89. Montagnese S, Biancardi A, Schiff S, et al. Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis. Hepatology 2011;53:558-66.
90. Odeh M. Pathogenesis of hepatic encephalopathy: the tumour necrosis factor-alpha theory. Eur J Clin Invest 2007;37:291-304.
91. Zieve L. The mechanism of hepatic coma. Hepatology 1981;1:360-5.
92. Campollo O, Sprengers D, McIntyre N. The BCAA/AAA ratio of plasma amino acids in three different groups of cirrhotics. Rev Invest Clin 1992;44:513-8.
93. Owen OE, Reichle FA, Mozzoli MA, et al. Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. J Clin Invest 1981;68:240-52.
94. Petrides AS, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth H. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998;28:141-9.
95. Sherwin RS, Fisher M, Bessoff J, et al. Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon. Gastroenterology 1978;74:1224-8.
96. Keiding S, Sorensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 2006;43:42-50.
97. Olde Damink SW, Deutz NE, Dejong CH, Soeters PB, Jalan R. Interorgan ammonia metabolism in liver failure. Neurochem Int 2002;41:177-88.
98. Olde Damink SW, Dejong CH, Deutz NE, et al. Kidney plays a major role in ammonia homeostasis after portasystemic shunting in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol 2006;291:G189-94.
99. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971;2:75-80.
100. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976;80: 77-91.
101. Morgan MY, Milsom JP, Sherlock S. Plasma ratio of valine, leucine and isoleucine to phenylalanine and tyrosine in liver disease. Gut 1978;19:1068-73.
102. Cuilleret G, Pomier-Layrargues G, Pons F, Cadilhac J, Michel H. Changes in brain catecholamine levels in human cirrhotic hepatic encephalopathy. Gut 1980;21:565-9.
103. Mpabanzi L, Deutz N, Hayes PC, Dejong CH, Olde Damink SW, Jalan R. Overnight glucose infusion suppresses renal ammoniagenesis and reduces hyperammonaemia induced by a simulated bleed in cirrhotic patients. Aliment Pharmacol Ther 2012;35:921-8.
104. Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013;58: 325-36.
105. McPhail MJ, Patel NR, Taylor-Robinson SD. Brain imaging and hepatic encephalopathy. Clin Liver Dis 2012;16: 57-72.
106. Rovira A, Alonso J, Cordoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol 2008;29: 1612-21.
107. Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portalsystemic shunting and liver dysfunction. Gastroenterology 1999;117:640-4.
108. Rama Rao KV, Reddy PV, Hazell AS, Norenberg MD. Manganese induces cell swelling in cultured astrocytes. Neurotoxicology 2007;28:807-12.
109. Weissenborn K, Ehrenheim C, Hori A, Kubicka S, Manns MP. Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluation. Metab Brain Dis 1995;10:219-31.
110. Marchetti P, D'Avanzo C, Orsato R, et al. Electroencephalography in patients with cirrhosis. Gastroenterology 2011;141:1680-9.
111. Timmermann L, Butz M, Gross J, et al. Impaired cerebral oscillatory processing in hepatic encephalopathy. Clin Neurophysiol 2008;119:265-72.
112. Montagnese S, Jackson C, Morgan MY. Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis. J Hepatol 2007;46:447-58.
113. Butterworth RF. Altered glial-neuronal crosstalk: cornerstone in the pathogenesis of hepatic encephalopathy. Neurochem Int 2010;57:383-8.
114. Butterworth RF. Hepatic encephalopathy: a central neuroinflammatory disorder? Hepatology 2011;53:1372-6.
115. Haussinger D, Gorg B. Interaction of oxidative stress, astrocyte swelling and cerebral ammonia toxicity. Curr Opin Clin Nutr Metab Care 2010;13:87-92.
116. Hertz L, Kala G. Energy metabolism in brain cells: effects of elevated ammonia concentrations. Metab Brain Dis 2007;22:199-218.
117. Lai JC, Cooper AJ. Brain alpha-ketoglutarate dehydrogenase complex: kinetic properties, regional distribution, and effects of inhibitors. J Neurochem 1986;47:1376-86.
118. Rama Rao KV, Jayakumar AR, Norenberg MD. Glutamine in the pathogenesis of acute hepatic encephalopathy. Neurochem Int 2012;61:575-80.
119. Leke R, Bak LK, Anker M, et al. Detoxification of ammonia in mouse cortical GABAergic cell cultures increases neuronal oxidative metabolism and reveals an emerging role for release of glucose-derived alanine. Neurotox Res 2011;19: 496-510.
120. Norenberg MD, Itzhak Y, Bender AS. The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. Adv Exp Med Biol 1997;420:95-111.
121. Szerb JC, Butterworth RF. Effect of ammonium ions on synaptic transmission in the mammalian central nervous system. Prog Neurobiol 1992;39:135-53.
122. Rodrigo R, Cauli O, Gomez-Pinedo U, et al. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology 2010;139:675-84.
123. Corenblum B, Shaffer EA. Hyperprolactinemia in hepatic encephalopathy may result from impaired central dopaminergic neurotransmission. Horm Metab Res 1989;21:675-7.
124. Lozeva V, Montgomery JA, Tuomisto L, et al. Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol 2004;40:742-48.
125. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding-an updated Cochrane review. Aliment Pharmacol Ther 2011;34: 509-18.
126. Alexander T, Thomas K, Cherian AM, Kanakasabapathy. Effect of three antibacterial drugs in lowering blood and stool ammonia production in hepatic encephalopathy. Indian J Med Res 1992;96:292-6.
127. Rolachon A, Zarski JP, Lutz JM, Fournet J, Hostein J. [Is the intestinal lavage with a solution of mannitol effective in the prevention of post-hemorrhagic hepatic encephalopathy in patients with liver cirrhosis? Results of a randomized prospective study]. Gastroenterol Clin Biol 1994;18:1057-62.
128. Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2011;26:996-1003.
129. American Academy of Clinical Toxicology and European Association of Poison Centers and Clinical Toxicologists. Position paper: cathartics. J Toxicol Clin Toxicol 2004;42: 243-53.
130. Soarez PC, Oliveira AC, Padovan J, Parise ER, Ferraz MB. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment. Arq Gastroenterol 2009;46:241-7.
131. Abid S, Jafri W, Mumtaz K, et al. Efficacy of L-ornithine-Laspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak 2011; 21:666-71.
132. Gluud LL, Dam G, Borre M, et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis 2013;28:221-5.
133. Rossi-Fanelli F, Riggio O, Cangiano C, et al. Branched-chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Dig Dis Sci 1982;27:929-35.
134. Higuchi K, Shimizu Y, Nambu S, et al. Effects of an infusion of branched-chain amino acids on neurophysiological and psychometric testings in cirrhotic patients with mild hepatic encephalopathy. J Gastroenterol Hepatol 1994;9:366-72.
135. Ott P, Clemmesen O, Larsen FS. Cerebral metabolic disturbances in the brain during acute liver failure: from hyperammonemia to energy failure and proteolysis. Neurochem Int 2005;47:13-8.
136. Plauth M, Cabre E, Campillo B, et al. ESPEN Guidelines on Parenteral Nutrition: hepatology. Clin Nutr 2009;28:436-44.
137. Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study. Eur J Emerg Med 1998;5:213-8.
138. Prabhakar S, Bhatia R. Management of agitation and convulsions in hepatic encephalopathy. Indian J Gastroenterol 2003;22 (Suppl 2): S54-8.
139. Hoetzel A, Ryan H, Schmidt R. Anesthetic considerations for the patient with liver disease. Curr Opin Anaesthesiol 2012;25:340-7.
140. Sharma P, Singh S, Sharma BC, et al. Propofol sedation during endoscopy in patients with cirrhosis, and utility of psychometric tests and critical flicker frequency in assessment of recovery from sedation. Endoscopy 2011;43: 400-5.
141. Clarke B, Ellis MJ, Leung V, et al. Reversal of hepatic encephalopathy and alteration in amino acid profiles after blocking a surgical splenorenal shunt by interventional radiological techniques. J Hepatol 1989;8:325-9.
142. Gentile S, Guarino G, Romano M, Alagia IA, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005;3:184-91.
143. Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005;11:7197-202.
144. Malaguarnera M, Vacante M, Motta M, et al. Acetyl-Lcarnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metab Brain Dis 2011;26:281-9.
145. Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther 2010;32:1080-90.
146. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med 1993;2:414-6.
147. Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2011;23:1250-7.
148. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and healthrelated quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011;106:307-16.
149. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2011;23:725-32.
150. Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 2011;33:662-71.
151. Malaguarnera M, Bella R, Vacante M, et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 2011;46:750-9.
152. Montagnese S, Amato E, Schiff S, et al. A patients' and caregivers' perspective on hepatic encephalopathy. Metab Brain Dis 2012;27:567-72.